Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
This platform enables us to develop bispecific T cell engagers that are potent and highly tumor specific. Our technology is designed to maximizing T cell-mediated cell killing effects with minimal cytokine release syndrome, and high stability and productivity. Leveraging this platform, we are developing multiple bispecific antibodies, including CM355(CD20xCD3), CM336(BCMAxCD3) and CM350(GPC3xCD3).
Company Profile Management Team Milestones
R&D Center Pipeline Manufacturing Park Cooperation
Corporate Governance Information Disclosure Financial Reports Stock Information IR Calendar Investor Presentations Email Alerts IR Contact
Latest News Media
Culture & Benefits
Contact Information Consultation Legal Statement Privacy
Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
蜀ICP备2022006281号